Schizophrenia FDA Approvals, Clinical Trials, Emerging Drugs, Pipeline Insights and Companies | DelveInsight
DelveInsight’s, “Schizophrenia Pipeline Insight” report provides comprehensive insights about 55+ companies and 60+ pipeline drugs in Schizophrenia pipeline landscape. It covers the Schizophrenia ...
Analysts reset AbbVie stock price target after earnings
For the full year 2025, the North Chicago company forecasts adjusted earnings per share of $12.12 to $12.32, in line with the ...
AbbVie's SWOT analysis: stock outlook strong despite humira loss
AbbVie Inc . (NYSE:ABBV), currently trading at $190.14, has demonstrated resilience and strategic foresight as it navigates the loss of exclusivity for its blockbuster drug Humira. The ...